Institute for Protein Design
The Institute for Protein Design develops novel proteins using artificial intelligence and computational methods for applications in medicine, therapeutics, sustainable chemistry, and environmental remediation. It aims to create custom-designed enzymes and protein structures to address challenges such as gene therapy delivery, biocatalysis, and plastic degradation.
Facts
- HQ
- Seattle, WA, USA
- Sectors
- Biotechnology, Protein design, Computational biology, AI/ML
Is this your organization? Claim it
Lila Bio wins $3.65M NIH SBIR grant to develop AI-designed long‑acting injectable for pulmonary hypertension
Lila Bio, spun out of David Baker’s UW lab, won a $3.65 million NIH SBIR grant to develop an AI-designed, long-acting injectable protein therapy aimed at modifying disease in pulmonary hypertension. The funding covers two phases—$605,981 for initial animal studies and $3,049,462 for further animal work and patient lung-tissue studies—and builds on Lila’s 2023 $10M seed raise and prior collaboration with Eli Lilly.
Lila Bio wins $3.65M NIH SBIR grant to develop AI-designed protein therapy for pulmonary hypertension
Lila Bio received a $3.65 million NIH SBIR grant to develop AI-designed, long-acting injectable protein therapies that aim to modify the underlying disease in pulmonary hypertension; initial work is in lab and animal testing with further studies planned using patient lung tissue.
GeekWire Weekly: Top stories include Rosie’s $7M raise, UW proposes splitting Allen School, Microsoft winds down The Garage, and John Collison nominated to Microsoft’s board
A roundup of GeekWire’s most-read technology and startup stories for the week of Oct. 18, 2026, covering Seattle startups, University of Washington governance changes, Microsoft program and board developments, and Amazon legal news.